In recent years, China's BPC industry has developed rapidly and China has become the world's largest BPC producer and exporter. Currently, the foreign trade is still at the stage of constant growth with promising prospect. The constant progress of new medical system reform and supporting measures has promoted the industrial structure change of China's pharmaceutical manufacturing industry, which brings great opportunities for China's pharmaceutical industry. The prosperous industrial development provides favorable development opportunity for "CPhI, ICSE & BioPh China".
The exhibition will gather the most cutting-edge information of the pharmaceutical markets and present a comprehensive one-stop pharmaceutical industry trade platform for over 2,500 exhibitors and over 40,000 professional purchasers coming from more than 20 countries.
The meeting adopts the form of "display-meeting" to make the world timely grasp the latest news of Chinese and global pharmaceutical markets and create opportunities for further developing markets. In order to better promote the information interaction between the audience and enterprises, and satisfy the demand of the audience and enterprises for the latest industrial information and technological exchanges, the organizer during the exhibition will meticulously plan high-end forum, professional seminar, technological exchange symposium among exhibitors and purchase matching and other activities in terms of domestic and international latest policies, regulations, hot topics of the industry and practical technology application.
In order to protect IPR, the organizer will screen the product catalogue of all participating companies before the exhibition, forbid enterprises with infringing products to participate and protect the image of "Made in China" on the international stage. During the exhibition, it will establish exhibition intellectual property office on the site together with Shanghai Intellectual Property Administration to receive the complaints from the owners of intellectual property and deal with relevant matters. Meanwhile, the organizer will work with the drug supervision and administration department to conduct random check on the quality of on-spot exhibits.
At present, China Chamber of Commerce has formulated work solutions for resisting illegal drugs. It plans to use the exhibition platform to resist and crack down on illegal behaviors in partnership with the national drug supervision and administration department so as to maintain the industrial image and normal operation order.
Rongda Pharm & Chem Co., Ltd is mainly involving in development, production and sales of pharm chemicals, fine chemicals, pharma intermediates, supplemented with AGRO chemicals. With the principle of 'to be honest, quality first, credit as our life”, we strive to make contributions to China pharm. And we will always try our best to provide our customer first class product. Warmly welcome friends from both home and abroad to cooperate with us.
In recent years, with the continuous development of the pharmaceutical industry, the pharmaceutical trade export has become a focus of concern to the industry. Export trade appeared serious polarization, the developed market remains in the doldrums, and the demand of emerging market is strong.
According to relevant statistics show that the first half of this year the number of China's pharmaceutical products export to Europe and the United States, Japan and other developed markets is growth of 3.27%. It accounted for 55.26 percent export market share and compared with the same period last year decreased by 2 percentage points. A long-term double-digit growth of China pharm dressing export is end, and up only slightly by 1.01 percent. Currently, from basic data analysis: China's medical dressing industry as a whole showed the characteristics is small market size and product homogeneity; the industry concentration degree is low; the value-added is not high. Along with market competition heats up, the enterprise competition is mainly concentrated in terms of price competition, and the industry is in the low level competition stage.
However, the characteristic API exports increased rapidly, and formulations exports will usher in rapid growth period. According to incomplete statistics, in the first half, China's characteristic API exported $1.067 billion, up 11.23% from a year earlier. And exporting to India, the United States, the European Union, Japan and South Korea mainly accounted for more than 80% of the market. The first half of the year, western medicine preparation exported USD $ 1357000000, up 7.93% from a year earlier. The pharmaceutical preparations exports is expected would usher in a new period of rapid growth in the second half of this year.
In the export trade rising market, the momentum of Chinese medicine export increase is the most rapid. Exports amounted to $ 491 million, up 22.49%. These increases were mainly from exports of Chinese herbal medicine and extracts increased significantly. Among them, the domestic prices of Chinese herbal medicine are continuous rise in the past two years, and last year international customers reduced the purchase quantity, especially in Japan and South Korea and the ASEAN customers. Resulting in a decline in inventories in the first half of this year, which in turn increase the purchase quantity, and it will stimulate the prices are further increases at the same time. The first half of the year, Chinese export prices and export volume compared with the same period last year increased by 30.44%, 8.24%. it is expected that it will continue to maintain this favorable situation in the second half.
Many domestic pharmaceutical companies optimistic about this situation, choose the right direction, and prepare to enter the field. And further optimize the export structure, effectively stimulating the export of Chinese medicine products to further growth.
Rongda Pharm & Chem Co., Ltd is mainly involving in development, production and sales of pharm chemicals, fine chemicals, pharma intermediates, supplemented with AGRO chemicals. With the principle of 'to be honest, quality first, credit as our life”, we will always try our best to provide our customer first class product. Warmly welcome friends from both home and abroad to cooperate with us.
As a major exporter of API, China encountered many difficulties in entering the market in Europe and the United States. Recently, China Chamber of Commerce for Import of Medicine &Health Products (Hereinafter referred to as CCCMHPIE) introduced: the first half of the year, China's pharmaceutical import and export trade amounted to USD $43.237 billion. It’s Up 10.28% from a year earlier. But since the third quarter, China's API export to Europe and the United States perhaps will into the most difficult period. In the first half of this year, the global economic growth momentum is insufficient; the international market demand has not been radically improved, leading to the international pharmaceutical trade volume decreased. Against this background, the development situation of China pharm foreign trade is more severe. It is embodied as prominent overcapacity contradictions, the downward pressure of economy increased, Sluggish external demand and rising costs, increasing trade friction and so on. Meanwhile, the vice president of CCCMHPIE Xu Ming also admitted that China's pharmaceutical trades probably enter to a relatively long complicated period in the second half of this year. And the unstable and uncertain factors will increase. Especially the traditional API market in Europe and the United States nearly saturated, and the prices are low. When the market demand in Europe and the United States is still difficult to have markedly improved, China's API export to Europe and the United States perhaps will into the most difficult period CCCMHPIE analysis, the recent main characteristics of China's pharmaceutical trade is: The developed market remains in the doldrums; strong emerging market demand ; export structure was further optimized; export transformation tension is growth; medical equipment and characteristic API increased sharply; Cost advantage declines; weaken the market competitiveness of medical dressings and disposable supplies. ‘Against such a backdrop, Emerging markets become China's API exports increment the only way.’ Xu Ming said. Data show that the first half of China’s API exports to emerging markets increased 10.03%. Among them, the medium-sized pharmaceutical enterprises to increase efforts to develop emerging markets and African markets. The number of top 100 pharmaceutical enterprises exports to emerging markets is increased by 12.2%. Rongda Pharm & Chem Co., Ltd is mainly involving in development, production and sales of pharm chemicals, fine chemicals, pharma intermediates, supplemented with AGRO chemicals. With the principle of 'to be honest, quality first, credit as our life”, we will always try our best to provide our customer first class product.Warmly welcome friends from both home and abroad to cooperate with us.
|
RSS Feed